

HAVE YOU OR SOMEONE YOU LOVE  
BEEN DIAGNOSED WITH STAGE 4  
NON-SMALL CELL LUNG CANCER  
(NSCLC) THAT HAS NEVER  
BEEN TREATED?

HARMONi.7



### About the HARMONi-7 Trial

- **Randomized:** Patients are randomly assigned into different groups
- **Double-blind:** Neither the participants nor the doctors know who is receiving which treatment
- **Global, phase 3 clinical trial** of ivonescimab versus pembrolizumab
- **Diagnosed with metastatic** (the cancer has spread), **non-small cell lung cancer** (mNSCLC)
- **For first-line treatment** (the patient has not been treated for mNSCLC)



HARMONi.7

## Have you or someone you love been diagnosed with stage 4 non-small cell lung cancer (NSCLC) that has never been treated?

If so, there is a phase 3 clinical trial called HARMONi-7 that you may want to ask your doctor about.



### What is the purpose of this clinical trial?

- The purpose of this trial is to learn whether a new investigational treatment called ivonescimab will work and be safe for the treatment of NSCLC that has spread. The study will compare the investigational treatment with an approved treatment called pembrolizumab.

### What is the clinical trial drug, ivonescimab?

- Ivonescimab is an investigational treatment, which works by blocking two separate targets in the body to decrease the cancer cells' ability to live, grow, and spread.

### Are you eligible for this clinical trial?

- You may be eligible if you have been diagnosed with stage 4 NSCLC and you have not received any prior therapy. Please talk with your doctor to determine if you are eligible.

### Your doctor can provide you with additional information but here are a few things to know:

- If you are eligible, what is involved? Once enrolled in the clinical trial, you will visit the clinic every three weeks for infusions. The treatment may continue for up to 24 months.
- You will receive regular blood tests and scans of your tumor.
- You will be regularly asked about any side effects or safety concerns you have, including worsening symptoms of previous illness.

### If you are in the clinical trial, will you receive ivonescimab?

- You will be randomly assigned to one of two treatment groups.
- Half the patients will be assigned to receive ivonescimab and the other half will receive pembrolizumab.
- Ivonescimab or pembrolizumab is administered by infusion (medication delivered into the body through the bloodstream instead of taking as pills or liquid).

Ivonescimab is an investigational therapy that is not presently approved by any regulatory authority other than China's National Medical Products Administration (NMPA).

# HARMONi-7



If you are interested in the  
HARMONi-7 Clinical Trial,  
please contact your doctor  
for more information.

**HARMONi-7**



Learn more by visiting [ClinicalTrials.gov](https://ClinicalTrials.gov)  
(Enter reference NCT06767514)

Or

Email [medinfo@smmmtx.com](mailto:medinfo@smmmtx.com)

Ivonescimab is an investigation drug that is being  
studied for its safety and effectiveness against  
the current standard treatment.



Summit Therapeutics and the Summit Therapeutics logo  
are trademarks of Summit Therapeutics Inc. Copyright 2025,  
Summit Therapeutics Inc. All Rights Reserved.

MAT-SMT112-0194\_V1

HARMONi-7Brochure/01.28.25